A fusion gene that results from chromosome rearrangements is a hybrid gene formed from distinct genes, either in the same chromosome or in different chromosomes. Many recurring gene fusions, such as BCR-ABL in chronic myelogenous leukemia, EWS-FIL1 in Ewing’s Sarcoma, and TMPRSS2-ERG in prostate cancer, play important roles in cancer progression. As such, they have become important therapeutic targets. Gene fusions are currently being discovered at an increasing rate using massively parallel sequencing technologies. Prioritization of important cancer fusion drivers for validation and as therapeutic targets cannot be performed using traditional single-gene based methods because fusions involve portions of two partner genes. To address this problem, Wu et al (Wu et al., 2013) have introduced a novel network analysis method called fusion centrality that is specifically tailored for prioritizing gene fusions. This fusion centrality approach is now integrated into the TARGETgene software developed previously, to prioritize fusion drivers from hundreds… Read more
Archive for 2013
ADAPT (version 5.0.046): The installation was updated to conform to Microsoft Visual Studio (MVS) 2012 for those user’s that chose the Intel Fortran option that does not include MVS. It is recommended, however, that you download and install the version of Intel Fortran with Microsoft Visual Studio 2010 Shell & Libraries included. A separate installation of MVS is then not needed.
ADAPT (version 5.0.045): The installation was updated to conform to Update 1 of Intel Fortran Composer 2013 (Intel’s current version of its Fortran Compiler) on both 32 and 64bit processors.